Blog
Advanced therapies in the UK
Across the UK, and indeed the world, there is significant growth and clinical progress being made in the field of advanced therapy medicinal products (ATMPs).
A brave new world for medical technologies
Boyds’ Vice President of Regulatory Affairs, Julie Warner, has co-edited an article in the October issue of the TOPRA journal, Regulatory Rapporteur, which focuses on medical
Supporting the creation of new biotech companies from academia
With the launch of Axovia Therapeutics, a biotech company in the gene therapy space, Dr. Nick Meyers, VP and Head of Product Development & Programme
Programme management: the backbone of successful product development
An increasing number of academic groups, new start-ups, biotechs and small pharma companies are turning to Boyds for professional programme management support and guidance to
Supporting the development of treatments for rare diseases – it’s in our DNA
To mark Rare Disease Day 2021, Professor Alan Boyd reflects on the work that he and his colleagues carry out to support the development of
Preventing fake medicines from reaching patients
Boyds’ Director of Regulatory Affairs, Julie Warner, has co-edited an article in the October issue of the TOPRA journal, Regulatory Rapporteur, which focuses on falsified
Overcoming the Barriers to the Development of Medicines for Ultra Rare Diseases
In the third and final article in the series on Orphan Drugs, Bryan Hurst discusses how to overcome the barriers to the development of medicines
Orphan Drug Development
This is the first in a series of articles aiming to highlight the vital role that drug development consultants play in helping small pharma companies
